Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Notable insider trades include Schobel Alexander Mark, Chief Innovation/Tech Officer at Aquestive Therapeutics Inc (AQST), who sold 50000 shares on Mar 15 ’24, at $6 each, totaling $0.30 million. On ...

Stock analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Illumina in a note issued to ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $14.53 per share for ...

Pharmaceuticals announced that it has commenced an underwritten public offering of shares of its common stock. Amylyx intends to ...

On Monday, Leerink Partners sustained their Outperform rating and $110.00 price target for Axsome Therapeutics (NASDAQ:AXSM) shares. The firm's stance comes in the wake of recent clinical trial ...

On Monday, Leerink Partners sustained their Outperform rating and $110.00 price target for Axsome Therapeutics (NASDAQ:AXSM) shares. The firm's stance comes in the wake of recent clinical trial ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...